HNSCC:	head and neck squamous cell carcinoma;
CAR-T:	chimeric antigen receptor T;
MHC:	non-major histocompatibility complex;
scFv:	single-chain variable fragment;
VL:	variable light chain;
VH:	variable heavy chain;
TRUCK:	T cells redirected for universal cytokine killing;
IL:	interleukin;
UniCAR-T:	universal CAR-T;
CRS:	cytokine release syndrome;
EGFR:	epidermal growth factor receptor;
GBM:	glioblastoma;
HER2:	human epidermal growth factor receptor 2;
GD2:	ganglioside D2;
FPA:	fibroblast activation protein;
MUC1:	mucin 1;
EpCAM:	epithelial cell adhesion molecule;
NKG2DL:	natural killer group 2 member D ligand;
LMP1:	latent membrane protein;
TME:	tumor microenvironment;
NIR:	near infrared
aPDL1:	anti-programmed death-ligand-1-blocking antibody;
PTT:	photothermal therapy;
CXCR:	C-X-C motif chemokine receptor;
HPSE:	heparinase;
TanCAR-T:	tandem CAR-T cells;
SUPRA:	split, universal and programmable;
OVs:	oncolytic viruses;
CAd:	binary oncolytic adenovirus;
PD-L1:	programmed cell death-ligand 1;
FHVH33:	humanized heavy-chain variable domain;
synNotch:	synthetic notch;
EphA2:	ephrin type A receptor 2;
iCAR-T:	inhibitory CAR-T;
iC9:	caspase-9;
CID:	chemical inducer of dimerization;
STAT3:	signal transducer and activator of transcription 3.